A Randomized Phase 3 Study Comparing Pemetrexed-Carboplatin With Docetaxel-Carboplatin as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2011
At a glance
- Drugs Carboplatin; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 07 Jul 2011 Results presented at the 14th World Conference on Lung Cancer.
- 04 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.